[
  {
    "title": "New Product Launches Benefit GMED Stock Amid Macro Issues",
    "published": 1742311740,
    "posting_price": 223.0,
    "close_price": 220.25,
    "percent_change": -1.23318386
  },
  {
    "title": "Why ResMed (RMD) is a Top Growth Stock for the Long-Term",
    "published": 1742219110,
    "posting_price": 222.3999939,
    "close_price": 224.74000549,
    "percent_change": 1.05216351
  },
  {
    "title": "NVIDIA's AI Speeds Up MedTech's Digital Boom: 3 Stocks in Focus",
    "published": 1741795560,
    "posting_price": 222.94000244,
    "close_price": 220.22000122,
    "percent_change": -1.22005974
  },
  {
    "title": "VEEV Stock Gains Following Latest Availability of HCP Access Data",
    "published": 1741366560,
    "posting_price": 224.42999268,
    "close_price": 232.44000244,
    "percent_change": 3.56904604
  },
  {
    "title": "5 Best Dividend Growth Stocks to Buy Amid Trade War Fears",
    "published": 1741184640,
    "posting_price": 227.71000671,
    "close_price": 223.83000183,
    "percent_change": -1.70392375
  },
  {
    "title": "ResMed Stock Climbs 25.6% in a Year: What's Driving the Rally?",
    "published": 1741175700,
    "posting_price": 227.71000671,
    "close_price": 223.83000183,
    "percent_change": -1.70392375
  },
  {
    "title": "VEEV Stock Falls Despite Latest Announcement to Enable AI Innovation",
    "published": 1741108260,
    "posting_price": 233.44000244,
    "close_price": 231.47999573,
    "percent_change": -0.83961904
  },
  {
    "title": "Integra Q4 Earnings Beat Estimates, Revenues Rise Y/Y, Stock Up",
    "published": 1741010700,
    "posting_price": 234.1000061,
    "close_price": 233.1000061,
    "percent_change": -0.42716787
  },
  {
    "title": "AMED Q4 Earnings and Revenues Miss, Margins Dip, Stock Rises",
    "published": 1741000440,
    "posting_price": 234.1000061,
    "close_price": 233.1000061,
    "percent_change": -0.42716787
  },
  {
    "title": "TransMedics Stock Rises as Q4 Earnings & Revenues Beat Estimates",
    "published": 1740760200,
    "posting_price": 231.47000122,
    "close_price": 233.52000427,
    "percent_change": 0.88564524
  },
  {
    "title": "Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down",
    "published": 1713070860
  },
  {
    "title": "Inogen: New Management And A Major Competitor Exit Offer Some New Opportunities",
    "published": 1712984592
  },
  {
    "title": "Analysts Are Bullish on Top Healthcare Stocks: InMode (INMD), Resmed (RMD)",
    "published": 1712926260,
    "posting_price": 186.92747406,
    "close_price": 184.19224548,
    "percent_change": -1.46325659
  },
  {
    "title": "Short interest in S&P 500 health stocks rises, Moderna among most shorted companies in March",
    "published": 1712924520,
    "posting_price": 186.92747406,
    "close_price": 184.19224548,
    "percent_change": -1.46325659
  },
  {
    "title": "ResMed Inc (RMD)'s Winning Formula: Financial Metrics and Competitive Strengths",
    "published": 1712743380,
    "posting_price": 189.00865517,
    "close_price": 192.0610199,
    "percent_change": 1.61493384
  },
  {
    "title": "Mizuho sees ResMed as 'overwhelming beneficiary' of Philips consent decree",
    "published": 1712718120,
    "posting_price": 189.00865517,
    "close_price": 192.0610199,
    "percent_change": 1.61493384
  },
  {
    "title": "Mizuho sees ResMed as \"overwhelming beneficiary\" of Philips consent decree",
    "published": 1712717400,
    "posting_price": 189.00865517,
    "close_price": 192.0610199,
    "percent_change": 1.61493384
  },
  {
    "title": "Jim Cramer Isn't Going With This Tech Company: 'It's Complicated. I'm A Nvidia Guy'",
    "published": 1712561460,
    "posting_price": 186.91758951,
    "close_price": 186.07521057,
    "percent_change": -0.45066863
  },
  {
    "title": "ResMed: Not A Sleeper",
    "published": 1712485316
  },
  {
    "title": "ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024",
    "published": 1712261100,
    "posting_price": 185.91665713,
    "close_price": 183.33998108,
    "percent_change": -1.38593071
  },
  {
    "title": "Resmed Inc Reports Increased CDIs in March",
    "published": 1712206200,
    "posting_price": 185.91665713,
    "close_price": 183.33998108,
    "percent_change": -1.38593071
  },
  {
    "title": "5 Medical Product Stocks to Buy Amid Industry Challenges",
    "published": 1712061300,
    "posting_price": 185.90674716,
    "close_price": 182.70573425,
    "percent_change": -1.72183794
  },
  {
    "title": "ResMed Inc. (NYSE:RMD) is a favorite amongst institutional investors who own 61%",
    "published": 1711990089,
    "posting_price": 196.53052179,
    "close_price": 187.62120056,
    "percent_change": -4.53330157
  },
  {
    "title": "Here's Why Investors Should Buy ResMed (RMD) Stock Now",
    "published": 1711989840,
    "posting_price": 196.53052179,
    "close_price": 187.62120056,
    "percent_change": -4.53330157
  },
  {
    "title": "S&P 500 stocks with the lowest hedge fund net exposure - BofA",
    "published": 1711966980,
    "posting_price": 196.53052179,
    "close_price": 187.62120056,
    "percent_change": -4.53330157
  },
  {
    "title": "ResMed price target raised by $9 at Needham, here's why",
    "published": 1711959600,
    "posting_price": 196.53052179,
    "close_price": 187.62120056,
    "percent_change": -4.53330157
  },
  {
    "title": "Analyst Upgrades Resmed Price Target to $224, Maintains Buy Rating Amidst Market Opportunities and OSA Trial Developments",
    "published": 1711946100,
    "posting_price": 196.53052179,
    "close_price": 187.62120056,
    "percent_change": -4.53330157
  }
]